top of page
Executive Spotlights

Incyte Corp. to Acquire Escient Pharmaceuticals for $750M

Wilmington, DE, April 23, 2024 (RTTNews) -- Incyte Corp. (INCY) is buying Escient Pharmaceuticals and its assets for $750 million, plus any cash left over when the deal closes. This acquisition needs approval under the Hart-Scott-Rodino Act and some standard conditions. If everything goes as planned, the deal could be finished by the third quarter of 2024.


Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma

Comments


Life Science Headlines
bottom of page